1. Home
  2. LNG vs EW Comparison

LNG vs EW Comparison

Compare LNG & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cheniere Energy Inc.

LNG

Cheniere Energy Inc.

HOLD

Current Price

$244.42

Market Cap

50.5B

Sector

Utilities

ML Signal

HOLD

Logo Edwards Lifesciences Corporation

EW

Edwards Lifesciences Corporation

HOLD

Current Price

$94.26

Market Cap

49.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNG
EW
Founded
1983
1958
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Industrial Specialties
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.5B
49.9B
IPO Year
1996
1999

Fundamental Metrics

Financial Performance
Metric
LNG
EW
Price
$244.42
$94.26
Analyst Decision
Strong Buy
Buy
Analyst Count
15
21
Target Price
$294.87
$96.37
AVG Volume (30 Days)
2.1M
4.1M
Earning Date
05-07-2026
04-23-2026
Dividend Yield
0.82%
N/A
EPS Growth
69.93
N/A
EPS
N/A
0.66
Revenue
$19,976,000,000.00
$6,067,600,000.00
Revenue This Year
$16.48
$13.39
Revenue Next Year
$5.89
$9.81
P/E Ratio
N/A
$142.91
Revenue Growth
27.21
11.55
52 Week Low
$186.20
$72.30
52 Week High
$300.94
$94.47

Technical Indicators

Market Signals
Indicator
LNG
EW
Relative Strength Index (RSI) 57.28 70.11
Support Level $220.29 $82.02
Resistance Level $255.48 N/A
Average True Range (ATR) 7.30 2.37
MACD 1.95 0.51
Stochastic Oscillator 84.50 99.12

Price Performance

Historical Comparison
LNG
EW

About LNG Cheniere Energy Inc.

Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.

About EW Edwards Lifesciences Corporation

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Share on Social Networks: